Terms: = Lymphoma AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568
9 results:
1. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract] [Full Text] [Related]
2. Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel slc34a2-ALK (exon 1: exon 15) fusion.
Zhou N; Wu M; Yuan M; Wu H; Yu S; Gao X; Wang Y
Lung Cancer; 2023 Sep; 183():107289. PubMed ID: 37542770
[TBL] [Abstract] [Full Text] [Related]
3. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
[TBL] [Abstract] [Full Text] [Related]
4. High expression of slc34a2 is a favorable prognostic marker in lung adenocarcinoma patients.
Zhang Z; Ye S; Zhang M; Wu J; Yan H; Li X; He J
Tumour Biol; 2017 Jul; 39(7):1010428317720212. PubMed ID: 28720066
[TBL] [Abstract] [Full Text] [Related]
5. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Ragon BK; Kantarjian H; Jabbour E; Ravandi F; Cortes J; Borthakur G; DeBose L; Zeng Z; Schneider H; Pemmaraju N; Garcia-Manero G; Kornblau S; Wierda W; Burger J; DiNardo CD; Andreeff M; Konopleva M; Daver N
Am J Hematol; 2017 Jan; 92(1):7-11. PubMed ID: 27673440
[TBL] [Abstract] [Full Text] [Related]
6. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract] [Full Text] [Related]
7. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract] [Full Text] [Related]
9. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
[TBL] [Abstract] [Full Text] [Related]
